Ephedra and the FDA

DSpace/Manakin Repository

dc.contributor.advisor	Hutt, Peter Barton	en_US
dc.contributor.author	Ehlers, Brandi E.	en_US
dc.date.accessioned	2012-06-07T20:27:11Z
dc.date.issued	2001	en_US
dc.identifier.citation	Ephedra and the FDA (2001 Third Year Paper)	en
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:8852148
dc.description.abstract	The adverse events experienced after ingesting ephedra and other dietary supplements have demonstrated the need for FDA intervention. The FDA has an important role to play in safeguarding the health and safety of the American public. The FDA has been criticized as contravening the Congressional intent underlying DSHEA because of its attempts to regulate the dietary supplement industry, when in fact, the FDA has not overstepped its bounds. The agency has only taken the measures it felt necessary to protect the public and "implement a complex and ambiguous law." However, the FDA does need to focus on more effective procedures and systems for collecting adverse event reports and could take additional steps toward public awareness. In order for the FDA to address the overall problems with the regulating the dietary supplement industry efficiently and effectively, they will need additional funding.	en
dc.language.iso	en_US	en
dash.license	LAA	en_US
dc.subject	Food and Drug Law	en
dc.subject	ephedra	en
dc.subject	FDA	en
dc.subject	regulation	en
dc.subject	dietary supplement	en
dc.title	Ephedra and the FDA	en
dc.type	Paper (for course/seminar/workshop)	en_US
dc.date.available	2012-06-07T20:27:11Z